4.2 Article

Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab

Related references

Note: Only part of the references are listed.
Article Rheumatology

Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study

J. E. Gehin et al.

Summary: The study indicated that golimumab concentrations >= 1.0 mg/L were associated with improved treatment response and better drug survival in patients with IJD. Some patients may benefit from higher drug concentrations. Therapeutic drug monitoring for dosing guidance in golimumab-treated patients with IJD is recommended based on the findings.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2021)

Review Immunology

Juvenile idiopathic arthritis-associated uveitis

Ethan S. Sen et al.

CLINICAL IMMUNOLOGY (2020)

Article Pediatrics

Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis

Andrea Skrabl-Baumgartner et al.

ARCHIVES OF DISEASE IN CHILDHOOD (2019)

Article Medicine, General & Internal

Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis

Athimalaipet V. Ramanan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Ophthalmology

Long-term Treatment with Golimumab for Severe Uveitis

Elisabetta Miserocchi et al.

OCULAR IMMUNOLOGY AND INFLAMMATION (2014)

Article Ophthalmology

Golimumab for Uveitis

Miguel Cordero-Coma et al.

OPHTHALMOLOGY (2011)

Article Ophthalmology

Switching biologic agents for uveitis

N. Dhingra et al.

Review Medicine, General & Internal

Cytokines and Chemokines in Uveitis - Is there a Correlation with Clinical Phenotype?

Kenneth G. -J. Ooi et al.

CLINICAL MEDICINE & RESEARCH (2006)

Editorial Material Ophthalmology

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

DA Jabs et al.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2005)